FAZA PET/MRI in CLI Patients Pre and Post Revascularization
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Aug 12, 2019
Trial Information
Current as of June 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging technique called FAZA PET/MRI to help better understand a condition known as Critical Limb Ischemia (CLI). CLI is a serious problem where blood flow to the legs is severely reduced, which can lead to pain, mobility issues, and even amputations. The trial aims to see how well this new imaging tool can assess the level of tissue damage caused by low oxygen in the legs, both before and after patients receive a procedure to improve blood flow. The researchers hope that this will help doctors predict which patients will benefit most from treatment and improve overall care for those with CLI.
To be eligible for the study, participants need to be at least 18 years old and have signs of CLI that make them candidates for a revascularization treatment. Women of childbearing age must have a negative pregnancy test and be able to provide consent to join the study. During the trial, participants will undergo a PET/MRI scan, which is a non-invasive procedure that allows doctors to see detailed images of the blood flow in their legs. This study is currently recruiting participants and aims to improve the understanding and treatment of CLI, potentially leading to better outcomes for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years;
- • Patients with clinical evidence of critical limb ischemia that are candidates for revascularization treatment;
- • A negative urine or serum pregnancy test in women of child-bearing age;
- • Ability to provide written informed consent to participate in the study.
- Exclusion Criteria:
- • Contraindication for MR as per current institutional guidelines;
- • Inability to lie supine for at least 30 minutes;
- • Pregnant or breastfeeding;
- • Unable or unwilling to provide informed consent;
- • Impending amputation within 6 weeks of presentation;
- • Previous metallic hardware in the lower limbs;
- • Unable to have ethanol.
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Patrick Veit-Haibach, MD
Principal Investigator
University Health Network, Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials